Nevertheless, those mixed clinical outcomes observed with GM-CSF-targeting therapies, particularly the failure of otilimab in rheumatoid arthritis trials, need cautious interpretation and warrant deeper critical analysis. The gene discussed is CSF2; the disease is rheumatoid arthritis.